Quarterly report · Q1
4578.TEDINET S100TCFM
Period2024-01-01 → 2024-03-31
Filed2024-04-30
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥519.5bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.02T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥448.3bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥92.0bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥76.8bn | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥100.1bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥142.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥79.2bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥77.4bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥121.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥61.4bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥78.9bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥62.7bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.45T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥3.36T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.13T | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥894.5bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥924.9bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.56T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.44T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.32T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.51T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.39T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.28T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥411.6bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥513.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥477.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥36.4bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥283.2bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥71.9bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥91.5bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥190.5bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥35.8bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥58.7bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.3bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥32.7bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥142.59 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥224.1 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥113.2 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥142.59 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥224.1 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥113.18 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.8% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.2% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.8% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-03-31 | ¥27.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-03-31 | ¥26.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥872m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥881m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥881m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-03-31 | −¥10.8bn |
| jpcrp040300-q1r_E21183-000Consumer Productsreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥7.3bn |
| jpcrp040300-q1r_E21183-000Consumer Productsreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥7.3bn |
| jpcrp040300-q1r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥1m |
| jpcrp040300-q1r_E21183-000Consumer Productsreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥4.3bn |
| jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥126.2bn |
| jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥126.2bn |
| jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥6m |
| jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥16.8bn |
| jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥359.6bn |
| jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥359.6bn |
| jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥79.8bn |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥520.4bn |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥519.5bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥881m |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | ¥102.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-03-31 | ¥27.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-03-31 | ¥26.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥723m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-03-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥742m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥742m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥12.9bn |
| jpcrp040300-q1r_E21183-000Consumer Productsreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥8.2bn |
| jpcrp040300-q1r_E21183-000Consumer Productsreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥8.2bn |
| jpcrp040300-q1r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥4m |
| jpcrp040300-q1r_E21183-000Consumer Productsreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥2.2bn |
| jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥104.0bn |
| jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥104.0bn |
| jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥13m |
| jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥10.8bn |
| jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥309.5bn |
| jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥309.5bn |
| jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥73.6bn |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥449.1bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥448.3bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥742m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | ¥89.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 694
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest paid ope cf IFRS | CurrentYTDDuration | -912000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -18792000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -38231000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 71882000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 36420000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | Prior1YTDDuration | 165000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | CurrentYTDDuration | 189000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -20235000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -25988000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -1739000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -14174000000 | JPY |
| Proceeds from sale of investments inv cf IFRS | Prior1YTDDuration | 39000000 | JPY |
| Proceeds from sale of investments inv cf IFRS | CurrentYTDDuration | 2084000000 | JPY |
| Purchase of investments inv cf IFRS | Prior1YTDDuration | -16102000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYTDDuration | -35680000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -2620000000 | JPY |
| Net decrease increase in time deposits inv cf IFRS | Prior1YTDDuration | 1916000000 | JPY |
| Net decrease increase in time deposits inv cf IFRS | CurrentYTDDuration | -15353000000 | JPY |
| Other inv cf IFRS | Prior1YTDDuration | 185000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | 83000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -35771000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -91459000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -0 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -0 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YTDDuration | 1797000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | 1014000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YTDDuration | 11000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYTDDuration | 150000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -4136000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -1567000000 | JPY |
| Redemption of bonds fin cf IFRS | Prior1YTDDuration | － | JPY |
| Redemption of bonds fin cf IFRS | CurrentYTDDuration | -20000000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -5044000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -5387000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -27308000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -32907000000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | Prior1YTDDuration | 2021000000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | CurrentYTDDuration | － | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -32659000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -58697000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | Prior1YTDDuration | 3451000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | CurrentYTDDuration | -113736000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 471634000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 513341000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 2051000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 12016000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 477137000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 411622000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E21183-000PharmaceuticalsReportableSegmentMember | 309532000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |